22,135,656
Vote Records
28,570
Companies
12,092
Funds
3,981
Managers

Home › Companies › INTELLIA THERAPEUTICS INC. › 2024-2025

INTELLIA THERAPEUTICS INC. 2024-2025 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and INTELLIA THERAPEUTICS INC.’s Form 8-K, filed June 12, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 7Reported items
  • 293Asset managers, any item
  • 2,069Fund votes
  • June 11, 2025Meeting date

Results at a glance

Meeting of June 11, 2025: 3 items on INTELLIA THERAPEUTICS INC.’s Form 8-K, filed June 12, 2025: 3 passed (calculated).

Dissent

Notable dissent: 1 director (18.6% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore INTELLIA THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by INTELLIA THERAPEUTICS INC.

These tallies are INTELLIA THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 12, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

INTELLIA THERAPEUTICS INC. — official shareholder meeting results, meeting held June 11, 2025
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: William Chase 62,680,7871,430,529402,742 --18,310,157 98%Passed (calculated)—
Elect Director: Georgia Keresty, Ph.D., M.P.H. 52,181,82411,931,333400,901 --18,310,157 81%Passed (calculated)—
Elect Director: John M. Leonard, M.D. 62,998,3851,440,68674,987 --18,310,157 98%Passed (calculated)—

Source: INTELLIA THERAPEUTICS INC., Form 8-K, filed with the SEC on June 12, 2025 — read the filing on EDGAR.

How asset managers voted at the INTELLIA THERAPEUTICS INC. 2024-2025 meeting

293 asset managers disclosed a vote on at least one INTELLIA THERAPEUTICS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of INTELLIA THERAPEUTICS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

Elect Director: Georgia Keresty, Ph.D., M.P.H.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

81% Majority: yes · of votes cast

FOR 81%AGAINST
FOR: 52,181,824AGAINST: 11,931,333
Details: description as filed, official tally, votes by 65 asset managers

Description as filed by funds: Election of three class III directors to our board of directors, each to serve until the 2028 annual meeting of stockholders and until their successor has been duly elected and qualified, or until their earlier death, resignation or removal: Georgia Keresty, Ph.D., M.P.H.

INTELLIA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Georgia Keresty, Ph.D., M.P.H.”): 52,181,824 for, 11,931,333 against, per its Form 8-K filed June 12, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 81% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 65 asset managers below reported 33,764,684 for, 1,409,770 against, 9,714 abstained.

FOR
FOR: 33,764,684AGAINST: 1,409,770ABSTAIN: 9,714
Largest asset managers voting on “Election of three class III directors to our board of directors, each to serve until the 2028 annual meeting o” at INTELLIA THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust11,989,5930 00For
Vanguard10,154,292844 00For
Capital Group3,779,4240 00For
BlackRock2,611,9910 00For
State Street2,258,6182,859 00For
Charles Schwab785,9460 00For
Fidelity539,1710 00For
Morgan Stanley376,0200 00For
Equitable214,503100,800 00Mixed
AMERICAN BEACON FUNDS257,7360 00For
TIAA255,8380 00For
American Century0188,987 00Against
Bridge Builder Trust46,35075,060 00Mixed
JPMorgan110,3280 00For
Global X0108,947 00Against
Victory Capital0105,749 00Against
Dimensional098,361 00Against
Lincoln Financial74,20011,780 00Mixed
QUANTITATIVE MASTER SERIES LLC83,3390 00For
AIG/SunAmerica071,235 00Against
Direxion Shares ETF Trust064,202 00Against
Thrivent062,564 00Against
ProShares056,826 00Against
SIT MUTUAL FUNDS INC055,400 00Against
MASTER INVESTMENT PORTFOLIO54,0280 00For

Showing the 25 largest of 65 asset managers. All 65 are in the interactive database (link above).

Elect Director: John M. Leonard, M.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 62,998,385AGAINST: 1,440,686
Details: description as filed, official tally, votes by 65 asset managers

Description as filed by funds: Election of three class III directors to our board of directors, each to serve until the 2028 annual meeting of stockholders and until their successor has been duly elected and qualified, or until their earlier death, resignation or removal: John M. Leonard, M.D.

INTELLIA THERAPEUTICS INC.’s own tally for this item (“Elect Director: John M. Leonard, M.D.”): 62,998,385 for, 1,440,686 against, per its Form 8-K filed June 12, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 65 asset managers below reported 34,920,552 for, 253,902 against, 9,714 abstained.

FOR
FOR: 34,920,552AGAINST: 253,902ABSTAIN: 9,714
Largest asset managers voting on “Election of three class III directors to our board of directors, each to serve until the 2028 annual meeting o” at INTELLIA THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust11,989,5930 00For
Vanguard10,155,1360 00For
Capital Group3,779,4240 00For
BlackRock2,611,9910 00For
State Street2,261,4770 00For
Charles Schwab785,9460 00For
Fidelity539,1710 00For
Morgan Stanley376,0200 00For
Equitable214,503100,800 00Mixed
AMERICAN BEACON FUNDS257,7360 00For
TIAA255,8380 00For
American Century188,9870 00For
Bridge Builder Trust121,4100 00For
JPMorgan110,3280 00For
Global X108,9470 00For
Victory Capital105,7490 00For
Dimensional098,361 00Against
Lincoln Financial81,1414,839 00Mixed
QUANTITATIVE MASTER SERIES LLC83,3390 00For
AIG/SunAmerica71,2350 00For
Direxion Shares ETF Trust64,2020 00For
Thrivent62,5640 00For
ProShares56,8260 00For
SIT MUTUAL FUNDS INC55,4000 00For
MASTER INVESTMENT PORTFOLIO54,0280 00For

Showing the 25 largest of 65 asset managers. All 65 are in the interactive database (link above).

Elect Director: William Chase

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 62,680,787AGAINST: 1,430,529
Details: description as filed, official tally, votes by 65 asset managers

Description as filed by funds: Election of three class III directors to our board of directors, each to serve until the 2028 annual meeting of stockholders and until their successor has been duly elected and qualified, or until their earlier death, resignation or removal: William Chase

INTELLIA THERAPEUTICS INC.’s own tally for this item (“Elect Director: William Chase”): 62,680,787 for, 1,430,529 against, per its Form 8-K filed June 12, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 65 asset managers below reported 34,917,067 for, 257,387 against, 9,714 abstained.

FOR
FOR: 34,917,067AGAINST: 257,387ABSTAIN: 9,714
Largest asset managers voting on “Election of three class III directors to our board of directors, each to serve until the 2028 annual meeting o” at INTELLIA THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust11,989,5930 00For
Vanguard10,155,1360 00For
Capital Group3,779,4240 00For
BlackRock2,611,9910 00For
State Street2,261,4770 00For
Charles Schwab785,9460 00For
Fidelity539,1710 00For
Morgan Stanley376,0200 00For
Equitable214,503100,800 00Mixed
AMERICAN BEACON FUNDS257,7360 00For
TIAA255,8380 00For
American Century188,9870 00For
Bridge Builder Trust121,4100 00For
JPMorgan110,3280 00For
Global X108,9470 00For
Victory Capital105,7490 00For
Dimensional098,361 00Against
Lincoln Financial81,1414,839 00Mixed
QUANTITATIVE MASTER SERIES LLC83,3390 00For
AIG/SunAmerica71,2350 00For
Direxion Shares ETF Trust64,2020 00For
Thrivent62,5640 00For
ProShares56,8260 00For
SIT MUTUAL FUNDS INC55,4000 00For
MASTER INVESTMENT PORTFOLIO54,0280 00For

Showing the 25 largest of 65 asset managers. All 65 are in the interactive database (link above).

Approval of the INTELLIA THERAPEUTICS, INC. 2025 equity incentive plan.

Combines 2 wordings of this item as funds reported it.

94% of fund votes cast · no official result

FOR
Details: description as filed, votes by 69 asset managers

Description as filed by funds: APPROVAL OF THE INTELLIA THERAPEUTICS, INC. 2025 EQUITY INCENTIVE PLAN.

The 69 asset managers below reported 33,144,651 for, 2,040,824 against, 0 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 33,144,651AGAINST: 2,040,824ABSTAIN: 0
Largest asset managers voting on “APPROVAL OF THE INTELLIA THERAPEUTICS, INC. 2025 EQUITY INCENTIVE PLAN.” at INTELLIA THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust11,989,5930 00For
Vanguard10,154,292844 00For
Capital Group3,779,4240 00For
BlackRock2,611,9910 00For
State Street2,257,8753,602 00For
Charles Schwab0785,946 00Against
Fidelity539,1710 00For
Morgan Stanley376,0200 00For
Equitable315,3030 00For
AMERICAN BEACON FUNDS257,7360 00For
TIAA255,8380 00For
American Century0188,987 00Against
Bridge Builder Trust46,35075,060 00Mixed
JPMorgan110,3280 00For
Global X0108,947 00Against
Victory Capital0105,749 00Against
Dimensional098,361 00Against
Lincoln Financial74,20011,780 00Mixed
QUANTITATIVE MASTER SERIES LLC83,3390 00For
AIG/SunAmerica071,235 00Against
Direxion Shares ETF Trust064,202 00Against
Thrivent062,564 00Against
ProShares056,826 00Against
SIT MUTUAL FUNDS INC055,400 00Against
MASTER INVESTMENT PORTFOLIO54,0280 00For

Showing the 25 largest of 69 asset managers. All 69 are in the interactive database (link above).

Approval, on a non-binding advisory basis, of the compensation of our named executive officers ("NEOs").

No official matchFund totals may overlapSECTION 14A SAY-ON-PAY VOTES

Combines 11 wordings of this item as funds reported it.

67% Fund and manager reports combined; may count the same shares twice · no official result

FORAGAINST
Details: votes by 291 asset managers

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports: 63 asset managers voting on “Approval, on a non-binding advisory basis, of the compensation of our named executive officers ("NEOs").” at INTELLIA THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust11,989,5930 00For
Vanguard10,154,287849 00For
Capital Group03,779,424 00Against
BlackRock2,611,9910 00For
State Street2,255,8275,650 00For
Charles Schwab0785,946 00Against
Fidelity539,1710 00For
Morgan Stanley376,0200 00For
Equitable214,503100,800 00Mixed
AMERICAN BEACON FUNDS257,7360 00For
TIAA0255,838 00Against
American Century0188,987 00Against
Bridge Builder Trust46,35075,060 00Mixed
JPMorgan110,3280 00For
Global X0108,947 00Against
Victory Capital0105,749 00Against
Dimensional098,361 00Against
Lincoln Financial74,20011,780 00Mixed
QUANTITATIVE MASTER SERIES LLC83,3390 00For
AIG/SunAmerica071,235 00Against
Direxion Shares ETF Trust064,202 00Against
Thrivent062,564 00Against
ProShares056,826 00Against
SIT MUTUAL FUNDS INC055,400 00Against
MASTER INVESTMENT PORTFOLIO54,0280 00For

Fund voting reports, all 63 managers: 28,925,442 for, 6,248,012 against, 9,714 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 246 asset managers voting on “Approval, on a non-binding advisory basis, of the compensation of our named executive officers ("NEOs").” at INTELLIA THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
State Street3,956,06953,772 00For
Capital Group03,779,424 00Against
BlackRock2,920,06949,187 00For
Nikko Asset Management Co., Ltd.02,825,361 00Against
Contrarius Group Holdings Ltd2,134,1430 00For
Morgan Stanley1,196,7030 00For
Two Sigma01,059,012 00Against
STIFEL NICOLAUS & CO INC \MO\0804,771 00Against
Charles Schwab0786,173 00Against
Northern Trust0487,179 00Against
Casdin Capital, LLC0469,463 00Against
ARMISTICE CAPITAL, LLC456,0000 00For
ARK Investment Management LLC391,8020 00For
UBS0388,474 00Against
GEODE CAPITAL MANAGEMENT, LLC357,5420 00For
Citadel349,0820 00For
Vestmark Advisory Solutions, Inc.0311,483 00Against
PARAMETRIC PORTFOLIO ASSOCIATES LLC0277,603 00Against
Nuveen0272,297 00Against
Vanguard262,6307,708 00For
Fidelity172,21782,601 00Mixed
BALYASNY ASSET MANAGEMENT L.P.0239,319 00Against
NOMURA ASSET MANAGEMENT CO LTD0233,730 00Against
American Century0189,121 00Against
Dimensional0159,153 00Against

Institutional-manager reports, all 246 managers: 12,632,927 for, 14,633,013 against, 1,665 abstained, 5,653 not voted, 31,094 1 year. Showing the 25 largest; every one is in the interactive database (link above).

Non-binding advisory vote on the frequency of future non-binding advisory votes on the compensation of our NEOs.

No official matchFund totals may overlapSECTION 14A SAY-ON-PAY VOTES

Combines 5 wordings of this item as funds reported it.

47.5% Fund and manager reports combined; may count the same shares twice · no official result

1 YEAR
Details: description as filed, votes by 288 asset managers

Description as filed by funds: A non-binding advisory vote on the frequency of future non-binding advisory votes on the compensation of our NEOs.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports: 63 asset managers voting on “A non-binding advisory vote on the frequency of future non-binding advisory votes on the compensation of our N” at INTELLIA THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust00 00--
Vanguard00 00--
Capital Group00 00--
BlackRock00 00--
State Street00 00--
Charles Schwab00 00--
Fidelity00 00--
Morgan Stanley00 00--
Equitable00 00--
AMERICAN BEACON FUNDS00 00--
TIAA00 00--
American Century00 00--
Bridge Builder Trust00 00--
JPMorgan00 00--
Global X00 00--
Victory Capital00 00--
Dimensional00 00--
Lincoln Financial6,9410 00For
QUANTITATIVE MASTER SERIES LLC00 00--
AIG/SunAmerica00 00--
Direxion Shares ETF Trust00 00--
Thrivent00 00--
ProShares00 00--
SIT MUTUAL FUNDS INC00 00--
MASTER INVESTMENT PORTFOLIO00 00--

Fund voting reports, all 63 managers: 6,941 for, 9,714 abstained, 35,023,171 1 year, 143,342 3 year, 0 unknown. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 243 asset managers voting on “A non-binding advisory vote on the frequency of future non-binding advisory votes on the compensation of our N” at INTELLIA THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
State Street00 00--
Capital Group00 00--
BlackRock00 00--
Nikko Asset Management Co., Ltd.00 00--
Contrarius Group Holdings Ltd00 00--
Morgan Stanley00 00--
Two Sigma00 00--
STIFEL NICOLAUS & CO INC \MO\00 00--
Charles Schwab00 00Not Voted
Northern Trust00 00--
Casdin Capital, LLC00 00--
ARMISTICE CAPITAL, LLC00 00--
ARK Investment Management LLC00 00--
UBS00 00--
GEODE CAPITAL MANAGEMENT, LLC00 00--
Citadel00 00--
Vestmark Advisory Solutions, Inc.00 00--
PARAMETRIC PORTFOLIO ASSOCIATES LLC00 00--
Nuveen00 00--
Vanguard00 00--
Fidelity00 00--
BALYASNY ASSET MANAGEMENT L.P.00 00--
NOMURA ASSET MANAGEMENT CO LTD00 00--
American Century00 00--
Dimensional00 00--

Institutional-manager reports, all 243 managers: 22,204 for, 32,189 against, 1,818 abstained, 3,753 not voted, 26,958,913 1 year, 202,381 3 year, 10,783 2 year, 50 unknown. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the…

No official matchAUDIT-RELATED

Combines 2 wordings of this item as funds reported it.

99.9% of fund votes cast · no official result

FOR
Details: description as filed, votes by 65 asset managers

Description as filed by funds: RATIFICATION OF THE APPOINTMENT OF DELOITTE & TOUCHE LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2025.

The 65 asset managers below reported 35,173,769 for, 685 against, 9,714 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 35,173,769AGAINST: 685ABSTAIN: 9,714
Largest asset managers voting on “RATIFICATION OF THE APPOINTMENT OF DELOITTE & TOUCHE LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM ” at INTELLIA THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust11,989,5930 00For
Vanguard10,155,1360 00For
Capital Group3,779,4240 00For
BlackRock2,611,9910 00For
State Street2,261,364113 00For
Charles Schwab785,9460 00For
Fidelity539,1710 00For
Morgan Stanley376,0200 00For
Equitable315,3030 00For
AMERICAN BEACON FUNDS257,7360 00For
TIAA255,8380 00For
American Century188,9870 00For
Bridge Builder Trust121,4100 00For
JPMorgan110,3280 00For
Global X108,9470 00For
Victory Capital105,7490 00For
Dimensional98,3610 00For
Lincoln Financial85,9800 00For
QUANTITATIVE MASTER SERIES LLC83,3390 00For
AIG/SunAmerica71,2350 00For
Direxion Shares ETF Trust64,2020 00For
Thrivent62,5640 00For
ProShares56,8260 00For
SIT MUTUAL FUNDS INC55,4000 00For
MASTER INVESTMENT PORTFOLIO54,0280 00For

Showing the 25 largest of 65 asset managers. All 65 are in the interactive database (link above).

Largest INTELLIA THERAPEUTICS INC. shareholders voting in 2024-2025

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 103,539,685 shares outstanding at the time of that meeting.

Fund voting reports: top INTELLIA THERAPEUTICS INC. shareholders by shares voted on “Approval, on a non-binding advisory basis, of the compensation of our named executive officers…”, 2024-2025
#Asset manager % of shares outstanding
1ARK ETF Trust 11.58%
2Vanguard 9.81%
3Capital Group 3.65%
4BlackRock 2.52%
5State Street 2.18%
6Charles Schwab 0.76%
7Fidelity 0.52%
8Morgan Stanley 0.36%
9Equitable 0.30%
10AMERICAN BEACON FUNDS 0.25%
Institutional-manager reports: top INTELLIA THERAPEUTICS INC. shareholders by shares voted on “Approval, on a non-binding advisory basis, of the compensation of our named executive officers…”, 2024-2025
#Asset manager % of shares outstanding
1State Street 3.87%
2Capital Group 3.65%
3BlackRock 2.87%
4Nikko Asset Management Co., Ltd. 2.73%
5Contrarius Group Holdings Ltd 2.06%
6Morgan Stanley 1.16%
7Two Sigma 1.02%
8STIFEL NICOLAUS & CO INC \MO\ 0.78%
9Charles Schwab 0.76%
10Northern Trust 0.47%

Reported INTELLIA THERAPEUTICS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

INTELLIA THERAPEUTICS INC. holdings and ownership disclosed for the 2024-2025 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
ARK Investment Management LLC14,207,324 13.72%Schedule 13G, filed February 3, 2026
Vanguard Group10,752,031 10.38%Form 13F, quarter ended March 31, 2025
BlackRock10,556,190 10.20%Form 13F, quarter ended March 31, 2025
Vanguard Portfolio Management6,266,007 6.05%Schedule 13G, filed April 29, 2026
State Street4,510,261 4.36%Form 13F, quarter ended March 31, 2025
Morgan Stanley3,801,695 3.67%Form 13F, quarter ended March 31, 2025
Citadel Advisors3,094,168 2.99%Form 13F, quarter ended March 31, 2025
Goldman Sachs2,445,583 2.36%Form 13F, quarter ended March 31, 2025
Two Sigma1,992,905 1.92%Form 13F, quarter ended March 31, 2025
Dimensional Fund Advisors1,968,166 1.90%Form 13F, quarter ended March 31, 2025

Percentages above are of 103,539,685 shares outstanding, as reported by INTELLIA THERAPEUTICS INC. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At INTELLIA THERAPEUTICS INC.'s shareholder meeting held June 11, 2025, in the 2024-2025 proxy season, 293 asset managers reported votes on at least one item in their SEC Form N-PX filings, covering 2,069 separate fund positions. Their filings are grouped here into 7 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. INTELLIA THERAPEUTICS INC.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — Approval, on a non-binding advisory basis, of the compensation of our named executive officers… — the reporting funds and managers cast 67% of the shares they voted in favour (FOR divided by FOR plus AGAINST plus WITHHELD; abstained and unvoted shares are excluded because neither took a side). Fund and manager reports are combined in it and may count the same shares twice: it adds fund reports to institutional-manager reports, which can cover the same shares. It is not the company's certified result.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from INTELLIA THERAPEUTICS INC.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

INTELLIA THERAPEUTICS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.

Cite this page

Proxy Votes Now, “INTELLIA THERAPEUTICS (NTLA) 2025 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/intellia-therapeutics-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.